These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15625379)

  • 21. Targeting targeted therapy.
    Green MR
    N Engl J Med; 2004 May; 350(21):2191-3. PubMed ID: 15118072
    [No Abstract]   [Full Text] [Related]  

  • 22. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
    Masago K; Fujita S; Irisa K; Kim YH; Ichikawa M; Mio T; Mishima M
    Jpn J Clin Oncol; 2010 Nov; 40(11):1105-9. PubMed ID: 20522446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
    J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular on/off switch.
    Milton DT; Riely GJ; Pao W; Miller VA; Kris MG; Heelan RT
    J Clin Oncol; 2006 Oct; 24(30):4940-2. PubMed ID: 17050880
    [No Abstract]   [Full Text] [Related]  

  • 25. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
    Yoshikawa S; Kukimoto-Niino M; Parker L; Handa N; Terada T; Fujimoto T; Terazawa Y; Wakiyama M; Sato M; Sano S; Kobayashi T; Tanaka T; Chen L; Liu ZJ; Wang BC; Shirouzu M; Kawa S; Semba K; Yamamoto T; Yokoyama S
    Oncogene; 2013 Jan; 32(1):27-38. PubMed ID: 22349823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
    Ushiki A; Koizumi T; Kobayashi N; Kanda S; Yasuo M; Yamamoto H; Kubo K; Aoyagi D; Nakayama J
    Jpn J Clin Oncol; 2009 Apr; 39(4):267-70. PubMed ID: 19155283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
    Yang TY; Tsai CR; Chen KC; Hsu KH; Lee HM; Chang GC
    J Clin Oncol; 2011 Jun; 29(16):e468-9. PubMed ID: 21422421
    [No Abstract]   [Full Text] [Related]  

  • 29. Medicine. Why a new cancer drug works well, in some patients.
    Marx J
    Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
    [No Abstract]   [Full Text] [Related]  

  • 30. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
    Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Mio T; Mishima M
    Oncol Rep; 2011 Oct; 26(4):795-803. PubMed ID: 21805046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
    Moiseyenko VM; Procenko SA; Levchenko EV; Barchuk AS; Moiseyenko FV; Iyevleva AG; Mitiushkina NV; Togo AV; Semionov II; Ivantsov AO; Matsko DE; Imyanitov EN
    Onkologie; 2010; 33(5):231-8. PubMed ID: 20502057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
    Ogino A; Kitao H; Hirano S; Uchida A; Ishiai M; Kozuki T; Takigawa N; Takata M; Kiura K; Tanimoto M
    Cancer Res; 2007 Aug; 67(16):7807-14. PubMed ID: 17699786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
    Lange T; Müller-Tidow C; Serve H; Hoffknecht P; Berdel WE; Thomas M
    Oncol Rep; 2005 Dec; 14(6):1539-42. PubMed ID: 16273252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
    Costa DB
    Lung Cancer; 2007 Aug; 57(2):251-2. PubMed ID: 17566601
    [No Abstract]   [Full Text] [Related]  

  • 37. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

  • 38. Gefitinib: phoenix from the flames.
    Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
    [No Abstract]   [Full Text] [Related]  

  • 39. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
    Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
    J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
    [No Abstract]   [Full Text] [Related]  

  • 40. EGFR mutations and sensitivity to gefitinib.
    Rossi G; Marchioni A; Longo L
    N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15376351
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.